Style | Citing Format |
---|---|
MLA | Yavarian J, et al.. "The Persistence Time of Sars-Cov-2 Rna in Hospitalized Covid-19 Patients: A Prospective Study." Infectious Disorders - Drug Targets, vol. 22, no. 6, 2022, pp. 56-64. |
APA | Yavarian J, Javaherian M, Malekshahi SS, Ahmadinejad Z, Ghiasvand F, Ahmadi E, Abbasian L, Hasannezhad M, Dabaghipour N, Shafieijandaghi NZ, Mokhtariazad T, Hajiabdolbaghi M (2022). The Persistence Time of Sars-Cov-2 Rna in Hospitalized Covid-19 Patients: A Prospective Study. Infectious Disorders - Drug Targets, 22(6), 56-64. |
Chicago | Yavarian J, Javaherian M, Malekshahi SS, Ahmadinejad Z, Ghiasvand F, Ahmadi E, Abbasian L, et al.. "The Persistence Time of Sars-Cov-2 Rna in Hospitalized Covid-19 Patients: A Prospective Study." Infectious Disorders - Drug Targets 22, no. 6 (2022): 56-64. |
Harvard | Yavarian J et al. (2022) 'The Persistence Time of Sars-Cov-2 Rna in Hospitalized Covid-19 Patients: A Prospective Study', Infectious Disorders - Drug Targets, 22(6), pp. 56-64. |
Vancouver | Yavarian J, Javaherian M, Malekshahi SS, Ahmadinejad Z, Ghiasvand F, Ahmadi E, et al.. The Persistence Time of Sars-Cov-2 Rna in Hospitalized Covid-19 Patients: A Prospective Study. Infectious Disorders - Drug Targets. 2022;22(6):56-64. |
BibTex | @article{ author = {Yavarian J and Javaherian M and Malekshahi SS and Ahmadinejad Z and Ghiasvand F and Ahmadi E and Abbasian L and Hasannezhad M and Dabaghipour N and Shafieijandaghi NZ and Mokhtariazad T and Hajiabdolbaghi M}, title = {The Persistence Time of Sars-Cov-2 Rna in Hospitalized Covid-19 Patients: A Prospective Study}, journal = {Infectious Disorders - Drug Targets}, volume = {22}, number = {6}, pages = {56-64}, year = {2022} } |
RIS | TY - JOUR AU - Yavarian J AU - Javaherian M AU - Malekshahi SS AU - Ahmadinejad Z AU - Ghiasvand F AU - Ahmadi E AU - Abbasian L AU - Hasannezhad M AU - Dabaghipour N AU - Shafieijandaghi NZ AU - Mokhtariazad T AU - Hajiabdolbaghi M TI - The Persistence Time of Sars-Cov-2 Rna in Hospitalized Covid-19 Patients: A Prospective Study JO - Infectious Disorders - Drug Targets VL - 22 IS - 6 SP - 56 EP - 64 PY - 2022 ER - |